Patent Exclusivity Reform Needed Due To Difficult Drug Environment – Hassan
The fixed post-approval exclusivity period should be extended in light of the lengthening of the development process, Schering-Plough CEO Fred Hassan suggested during an interview with "The Pink Sheet"
You may also be interested in...
FDA should expand and improve its external communications programs, panelists said during the FDA Alumni Association annual meeting in Washington, D.C. April 5
Offering extended exclusivity, in advance, for drugs that address an unmet medical need could bring a necessary boost to research and development efforts, Vanderbilt University's Alastair Wood said
The solution to the "innovation threat" facing big pharma lies in making deals outside the company, Schering-Plough CEO Fred Hassan said during an R&D update Nov. 1